GEN Exclusives

More »

GEN News Highlights

More »
Sep 14, 2007

Indivumed to Provide Roche Diagnostics with Immunohistochemistry Services and Clinical Specimens

  • Indivumed will analyze various biomarkers and drug targets in the area of oncology for Roche Diagnostics. This should enable Roche to efficiently develop novel targeted therapies for cancer, the companies note.

    Indivumed will apply its automated immunohistochemistry (IHC) service platform. It will also provide a selection of tumor tissue sections from its tumor biobank as well as specifically collected clinical samples.

    Indivumed currently has a tumor biobank of over 6,500 patient cases, the company reports. It is a resource for the firm’s internal cancer research in biomarkers and primary cell drug screening as well as for for pharmaceutical and biopharma partners through tumor biobank access and IHC services.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »